Evidence map›Paper›PMID 28751717›Full record

ArticleScientific reports2017

Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain.

Rafael Sivera, Marina Frasquet, Vincenzo Lupo, Tania García-Sobrino, Patricia Blanco-Arias, Julio Pardo, Roberto Fernández-Torrón, Adolfo López de Munain, Celedonio Márquez-Infante, Liliana Villarreal and 22 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Clinical and Neuroimaging Features in Charcot-Marie-Tooth Patients withJournal of clinical neurology (Seoul, Korea) · 2021
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 18 institutions in 3 countries.

Rafael SiveraDepartment of Neurology, Hospital Francesc de Borja, Gandía, Spain. rafasivera@gmail.com.
Marina FrasquetDepartment of Neurology, Hospital Universitari i Politécnic La Fe, Valencia, Spain.
Vincenzo LupoUnit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders and Service of Genomics and Traslational Geneticis, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
Tania García-SobrinoDepartment of Neurology, Hospital Clínico, Santiago de Compostela, Spain.
Patricia Blanco-AriasNeurogenetics Research Group, Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain.
Julio PardoDepartment of Neurology, Hospital Clínico, Santiago de Compostela, Spain.
Roberto Fernández-TorrónNeuromuscular Disorders Unit, Neurology Department, Hospital Donostia, San Sebastián, Spain.
Adolfo López de MunainNeuromuscular Disorders Unit, Neurology Department, Hospital Donostia, San Sebastián, Spain.
Celedonio Márquez-InfanteDepartment of Neurology and Neurophysiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Liliana VillarrealDepartment of Neurology and Neurophysiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Pilar CarbonellDepartment of Neurology and Neurophysiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Ricard Rojas-GarcíaCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
Sonia SegoviaCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
Isabel IllaCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
Anna Lia FrongiaNeuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Deu, Barcelona, Spain.
Andrés NascimentoCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
Carlos OrtezCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
María Del Mar García-RomeroNeuropaediatrics Department, Hospital la Paz, Madrid, Spain.
Samuel Ignacio PascualNeuropaediatrics Department, Hospital la Paz, Madrid, Spain.
Ana Lara Pelayo-NegroCenter for Biomedical Research in the Neurodegenerative Diseases (CIBERNED) Network, Instituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
José BercianoCenter for Biomedical Research in the Neurodegenerative Diseases (CIBERNED) Network, Instituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
Antonio GuerreroNeuromuscular Diseases Unit, Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain.
Carlos CasasnovasNeuromuscular Diseases Unit, Department of Neurology, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain.
Ana CamachoChild Neurology Unit, Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Jesús EstebanDepartment of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain.
María José ChumillasDepartment of Neurophysiology, Hospital Universitari I Politécnic La Fe, Valencia, Spain.
Marisa BarreiroNeuromuscular Research Unit, Instituto de Investigación Sanitaria la Fe (IIS La Fe), Valencia, Spain.
Carmen DíazDepartment of Neurology, Hospital General de Alicante, Alicante, Spain.
Francesc PalauCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
Juan Jesús VílchezDepartment of Neurology, Hospital Universitari i Politécnic La Fe, Valencia, Spain.ORCID 0000-0002-0532-2872
Carmen EspinósUnit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders and Service of Genomics and Traslational Geneticis, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
Teresa SevillaDepartment of Neurology, Hospital Universitari i Politécnic La Fe, Valencia, Spain.ORCID 0000-0003-4716-2667
Hospital Sant Joan de Déu Barcelona · ESHospital Universitario Virgen del Rocío · ESCentre for Biomedical Network Research on Rare Diseases · ESCentro de Investigacion Principe Felipe · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario La Paz · ESUniversidad de Cantabria · ESUniversitat Autònoma de Barcelona · ESUniversitat de València · ESBellvitge University Hospital · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESHospital Clínico San Carlos · ESHospital General Universitario de Alicante Doctor Balmis · ESHospital Universitario 12 De Octubre · ESInstituto de Investigación Sanitaria La Fe · ESRafael Advanced Defense Systems (Israel) · ILUniversidad Complutense de Madrid · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in the GDAP1 gene can cause Charcot-Marie-Tooth disease. These mutations are quite rare in most Western countries but not so in certain regions of Spain or other Mediterranean countries. This cross-sectional retrospective multicenter study analyzed the clinical and genetic characteristics of patients with GDAP1 mutations across Spain. 99 patients were identified, which were distributed across most of Spain, but especially in the Northwest and Mediterranean regions. The most common genotypes were p.R120W (in 81% of patients with autosomal dominant inheritance) and p.Q163X (in 73% of autosomal recessive patients). Patients with recessively inherited mutations had a more severe phenotype, and certain clinical features, like dysphonia or respiratory dysfunction, were exclusively detected in this group. Dominantly inherited mutations had prominent clinical variability regarding severity, including 29% of patients who were asymptomatic. There were minor clinical differences between patients harboring specific mutations but not when grouped according to localization or type of mutation. This is the largest clinical series to date of patients with GDAP1 mutations, and it contributes to define the genetic distribution and genotype-phenotype correlation in this rare form of CMT.

Indexed as

Genetic Association StudiesMutationAdolescentAdultAgedCharcot-Marie-Tooth DiseaseChildChild, PreschoolCross-Sectional StudiesFemaleGeography, MedicalHumansMaleMiddle AgedNerve Tissue ProteinsRetrospective StudiesGDAP proteinNerve Tissue Proteins

Identifiers

PMID28751717
PMCPMC5532232
OpenAlexW2738016419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.